ITCI (Intra-Cellular Therapies Inc.) Return on Sales by Net Profit

Is it worth investing in a scalable neuro-drug business with global expansion potential? The revenue margin provides the answer, where -11.00 becomes the new value of the indicator. Growth in recurring revenues from Caplyta ensures high profits and free cash flow for Intra-Cellular Therapies (ITCI). However, there is a dependency on insurance coverage rates and the dominance of a single core product.
Intra-Cellular Therapies Inc. (ITCI) - metric breakdowns and financial figures

Scaling neuro-drug sales in the US directly impacts the cost management efficiency of Intra-Cellular Therapies (ITCI). This metric measures the share of net income in total revenue, reflecting the business's bottom-line profitability. Investors utilize this metric to assess the company's ability to convert market growth into actual income. Analyzing the company's net profit margin allows for the filtering out of short-term anomalies. A stable trend in this line confirms the resilience of the asset's fundamental value.